v3.26.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table reconciles reported revenues to net loss under the significant expense principle for the three and nine months ended September 30, 2026 and 2025:
Three Months Ended September 30,Nine Months Ended
September 30,
2026202520262025
Revenues$7,557 $12,807 $35,822 $31,530 
Costs and expenses:
Total Manufacture and Supply Expenses
3,606 4,506 11,092 12,719 
R&D Project expenses:
Anaphylm project expenses
1,179 912 3,319 4,604 
AQST-108 project expenses294 (131)1,004 254 
R&D other expenses:
Personnel costs1
2,218 3,001 6,641 7,351 
Other2
560 748 1,453 1,787 
Total Research and Development Expenses
4,251 4,530 12,417 13,996 
Selling expenses:
Personnel costs3
1,740 805 5,114 2,108 
Other4
2,006 3,110 2,726 8,283 
Total Selling expenses
3,746 3,915 7,840 10,391 
General & Administrative expenses:
Personnel costs5
5,405 5,017 17,516 15,025 
Other6
5,018 6,318 13,853 21,611 
Total General and Administrative Expenses
10,423 11,335 31,369 36,636 
Total Selling, General and Administrative Expenses
14,169 15,250 39,209 47,027 
Total costs and expenses22,026 24,286 62,718 73,742 
Loss from operations(14,469)(11,479)(26,896)(42,212)
Other income/(expenses), net
(2,027)(3,967)(20,521)(9,712)
Net loss before income taxes(16,496)(15,446)(47,417)(51,924)
Net loss$(16,496)$(15,446)$(47,417)$(51,924)
Comprehensive loss$(16,496)$(15,446)$(47,417)$(51,924)
1 - R&D Personnel costs include payroll expenses, share-based compensation expenses and severance
2 - Other R&D expenses include preclinical, consulting, maintenance, and testing fees
3 - Selling Personnel costs include payroll expenses, share-based compensation expenses and severance
4 - Other Selling expenses include commercialization and other related expenses
5 - G&A Personnel costs include payroll expenses, share-based compensation expenses and severance
6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs